Evidence map›Paper›PMID 42791432›Full record

ArticleJournal of gastrointestinal cancer2026

Global Perspectives on Radiotherapy Utilization for Pancreatic Ductal Adenocarcinoma.

Bradley N Reames, Eric D Miller, Ziyi Zhou, Amol Narang, Patrick L Quinn, Bradley White, Emile Gogineni, Aslam Ejaz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Bradley N ReamesDepartment of Surgery, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Eric D MillerDepartment of Radiation Oncology, Ohio State University, Columbus, OH, USA.
Ziyi ZhouDepartment of Surgery, University of Illinois Chicago, 840 S. Wood Street, CSB 618, Chicago, IL, 60613, USA.
Amol NarangDepartment of Radiation Oncology, Johns Hopkins Hospital, Baltimore, MD, USA.
Patrick L QuinnDepartment of Surgery, Ohio State University, Columbus, OH, USA.
Bradley WhiteDepartment of Surgery, University of Illinois Chicago, 840 S. Wood Street, CSB 618, Chicago, IL, 60613, USA.
Emile GogineniDepartment of Radiation Oncology, Ohio State University, Columbus, OH, USA.
Aslam EjazDepartment of Surgery, University of Illinois Chicago, 840 S. Wood Street, CSB 618, Chicago, IL, 60613, USA. aejaz@uic.edu.ORCID https://orcid.org/0000-0002-1387-2604

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy requiring multi-modality treatment. Radiotherapy (RT) may improve local control and resection rates, though evidence to support use across various stages of disease is mixed and evolving. This study sought to investigate international practice patterns and provider preferences for the use of radiotherapy in the multidisciplinary management of PDAC.

methodsA 39-item electronic survey was distributed in 2025 through three sub-specialty organizations to providers who have recently treated PDAC.

resultsA total of 176 PDAC providers from six continents completed the survey, with the majority practicing in Europe (n= 76, 43%) and North America (n= 62, 35%). Respondents included mostly surgeons (n= 143, 81%) with 81% (n= 142) practicing in academic centers. Nearly 1 in 5 respondents did not offer or consider any indication for neoadjuvant (n= 32, 19%) or adjuvant (n= 46, 30%) RT. The most commonly cited indication for neoadjuvant RT was for locally advanced disease (n= 88, 52%) and surgically unresectable disease (n= 86, 51%), while the use of adjuvant RT was primarily for positive surgical margins (n= 97, 63%) and positive nodal disease (n= 46, 30%).

conclusionIn an international cohort of surgeons and radiation oncologists, there is substantial variation in perceptions of effectiveness, management preferences, and the propensity to utilize radiotherapy for PDAC. These results underscore the lack of strong evidence to support management, and the need for consensus guidelines and clinical trials to inform best practice.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsPractice Patterns, Physicians'Combined Modality TherapyFemaleHumansNeoadjuvant TherapyRadiotherapy, AdjuvantSurveys and QuestionnairesAdjuvant therapyMulti-modality treatmentNeoadjuvant therapyPancreatic ductal adenocarcinomaPractice patternsRadiotherapy

Identifiers

PMID42791432
PMCPMC13615146

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.